Daihan Pharmaceutical Co.Ltd Asset Resilience Ratio
Daihan Pharmaceutical Co.Ltd asset resilience ratio. Daihan Pharmaceutical Co.Ltd (023910) has an Asset Resilience Ratio of 11.95% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Daihan Pharmaceutical Co.Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Daihan Pharmaceutical Co.Ltd (2014–2024)
Asset resilience ratio of Daihan Pharmaceutical Co.Ltd from 2014 to 2024. This chart shows how Daihan Pharmaceutical Co.Ltd's Asset Resilience Ratio has changed over time. Read 023910 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Daihan Pharmaceutical Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Daihan Pharmaceutical Co.Ltd balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩41.12 Billion | 11.95% |
| Total Liquid Assets | ₩41.12 Billion | 11.95% |
Asset Resilience Insights
- Moderate Liquidity: Daihan Pharmaceutical Co.Ltd has 11.95% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Daihan Pharmaceutical Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Daihan Pharmaceutical Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Daihan Pharmaceutical Co.Ltd Asset Resilience Ratio by Year (2014–2024)
Daihan Pharmaceutical Co.Ltd asset resilience ratio by year from 2014 to 2024. The table below shows the annual Asset Resilience Ratio data for Daihan Pharmaceutical Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 23.79% | ₩77.18 Billion ≈ $52.31 Million |
₩324.41 Billion ≈ $219.85 Million |
-11.66pp |
| 2023-12-31 | 35.45% | ₩104.32 Billion ≈ $70.70 Million |
₩294.25 Billion ≈ $199.41 Million |
+0.31pp |
| 2022-12-31 | 35.14% | ₩97.34 Billion ≈ $65.97 Million |
₩276.98 Billion ≈ $187.71 Million |
-0.22pp |
| 2021-12-31 | 35.36% | ₩96.38 Billion ≈ $65.31 Million |
₩272.54 Billion ≈ $184.70 Million |
+8.69pp |
| 2020-12-31 | 26.67% | ₩67.50 Billion ≈ $45.75 Million |
₩253.09 Billion ≈ $171.52 Million |
+4.89pp |
| 2019-12-31 | 21.78% | ₩53.77 Billion ≈ $36.44 Million |
₩246.85 Billion ≈ $167.29 Million |
+3.63pp |
| 2018-12-31 | 18.15% | ₩42.60 Billion ≈ $28.87 Million |
₩234.75 Billion ≈ $159.09 Million |
+9.43pp |
| 2017-12-31 | 8.72% | ₩16.08 Billion ≈ $10.90 Million |
₩184.40 Billion ≈ $124.97 Million |
+1.04pp |
| 2016-12-31 | 7.68% | ₩12.31 Billion ≈ $8.34 Million |
₩160.31 Billion ≈ $108.64 Million |
+5.89pp |
| 2015-12-31 | 1.79% | ₩2.48 Billion ≈ $1.68 Million |
₩138.83 Billion ≈ $94.08 Million |
-0.37pp |
| 2014-12-31 | 2.16% | ₩2.84 Billion ≈ $1.92 Million |
₩131.61 Billion ≈ $89.19 Million |
-- |
About Daihan Pharmaceutical Co.Ltd
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.